Articles On Telix Pharmaceuticals (ASX:TLX)
Title | Source | Codes | Date |
---|---|---|---|
ASX Close: Strong end to losing month as rate rise looms
The share market ended a volatile month on a strong note, advancing for a second day ahead of a likely rate rise next week. The S&P/ASX 200 climbed 78 points or 1.06 per cent. The rally trimmed the benchmark’s loss for the month to 6... |
themarketherald.com.au | TLX | 2 years ago |
ASX Update: Market trims April losses as tech shines
A broad rally carried the share market towards a second day of gains at the end of a challenging month for investors. All 11 sectors rose as the S&P/ASX 200 put on 58 points or 0.79 per cent. The advance trimmed the index’s loss for... |
themarketherald.com.au | TLX | 2 years ago |
48% fall: Fund names 3 ASX shares to take off after heavy crash
The first few months of 2022 has seen share market volatility like we could not even imagine last year. This means that quite a few businesses have seen their stock fall like a stone. Yet their operations and fortunes may not have changed... |
Motley Fool | TLX | 2 years ago |
ASX Close: Win run flames out as holiday caution prevails
A week-long rally soured with the share market’s heaviest loss in two months as investors took profits ahead of the long weekend. The S&P/ASX 200 slumped 119.5 points or 1.57 per cent to its first loss in six sessions. The reversal p... |
themarketherald.com.au | TLX | 2 years ago |
Telix Pharmaceuticals (ASX:TLX) reports on its March Quarter
22 Apr 2022 - Telix Pharmaceuticals (ASX:TLX) reported on its March quarter, with focus placed on its prostate cancer product. |
FNN | TLX | 2 years ago |
Telix share price slips on quarterly update
The Telix Pharmaceuticals Ltd (ASX: TLX) share price is sliding today and is now 1.96% in the red at $4.51. Investors appear to have been unimpressed by Telix’s quarterly activities and cash flow report today, with trading volume less tha... |
Motley Fool | TLX | 2 years ago |
ASX Update: Traders lock in profits before long weekend
The share market backed off an eight-month high after a sharp reversal on Wall Street stoked risk aversion ahead of the long weekend. The S&P/ASX 200 skidded 124 points or 1.63 per cent by mid-session. The decline ended a five-sess... |
themarketherald.com.au | TLX | 2 years ago |
ASX Update: BHP downgrades hamper record push
A disappointing quarterly from mining heavyweight BHP crimped a fifth day of share market gains as the ASX 200 edged closer to record territory. The Australian benchmark climbed to within 0.5 per cent of last year’s peak, rising 31 point... |
themarketherald.com.au | TLX | 2 years ago |
ASX 200 healthcare shares were chronically ill last quarter. Take a look
ASX 200 healthcare shares have struggled for the past six months, let’s face it. After peaking at 52-week highs of 47,760 back in September 2021, the S&P/ASX 200 Health Care Index (ASX: XHJ) now rests at 39,861. That’s a 16.5% decline... |
Motley Fool | TLX | 2 years ago |
ASX Close: Shares trim gains as bond sell-off continues
Aussie shares pared solid early gains as rising rates and stronger-than-expected Chinese consumer prices sharpened global inflation worries ahead of tomorrow’s US data. The S&P/ASX 200 slashed an early 47-point surge to seven points... |
themarketherald.com.au | TLX | 2 years ago |
Telix (ASX:TLX) enters licence agreement for cancer treatment
11 Apr 2022 - Telix Pharmaceuticals (ASX:TLX) has entered into a licence agreement with Eli Lilly, which grants Telix rights to develop and commercialise radiolabelled forms of Lil… |
FNN | TLX | 2 years ago |
Telix (ASX:TLX) strikes licence agreement with Lilly for cancer treatment
Telix Pharmaceuticals (ASX:TLX) signs an exclusive licence agreement with Eli Lilly to develop its cancer antibody medication olaratumab Telix will pay Lilly an initial US$5 million (A$6.7 million) for the rights to its radiolabelled forms... |
themarketherald.com.au | TLX | 2 years ago |
ASX Update: Early gains evaporate as Asia, US futures sink
The share market hit a four-session high before turning negative as US futures signalled potential weakness tonight. The S&P/ASX 200 reached mid-session a point or 0.01 per cent lower after earlier gaining 47 points. The early rally... |
themarketherald.com.au | TLX | 2 years ago |
Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab
MELBOURNE, Australia and INDIANAPOLIS, April 11, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, "Telix", the "Company") today announces that it has entered into a licence agreement with Eli Lilly and Company ("Lilly") under... |
FNArena | TLX | 2 years ago |
ScoPo’s Powerplays: Green shoots appear among smaller ASX health stocks
S&P/ASX 200 healthcare index modestly up 0.16% for week Gut health company Microba falls on IPO Rhythm Biosciences bowel cancer blood screening test milestone Have a habit of forgetting where you put your keys or mobile phone? You ma... |
Stockhead | TLX | 2 years ago |
PSMA-PET Imaging to be Funded through Medicare in Australia from July 2022
MELBOURNE, Australia, April 6, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) welcomes the listing of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) (PSMA-PET) imaging for p... |
FNArena | TLX | 2 years ago |
March In Review: War Puts ASX On Pedestal
Gains in the resources, banking and technology sectors contributed to a 6.9% total return for the ASX200 in March, as Australia continued to outperform global equity markets. -The ASX200 gained 6.9% (total return) during March-Value continu... |
FNArena | TLX | 2 years ago |
Telix Pharmaceuticals confirms US commercial launch of Illuccix
Telix Pharmaceuticals (ASX:TLX) has announced that its prostate cancer imaging agent Illuccix, also known as 68Ga-PSMA-11 injection, is now commercially available in the US. |
BiotechDispatch | TLX | 2 years ago |
ASX Large Caps: Blue chips on a roll as investors shrug off recession fears
ASX 200 extends winning streak US bonds have sharply inverted, sparking concerns of a potential recession China says it has found a new Omicron sub-variant It was a sea of green today on the ASX, as local investors shrugged off a rapid... |
Stockhead | TLX | 2 years ago |
Here’s why the Telix (ASX:TLX) share price surged 10% today
The Telix Pharmaceuticals Ltd (ASX: TLX) share price took off today after the company released news of its lead product and a $23 million funding package. Telix’s prostate cancer imaging agent Illuccix is now available for order in the U... |
Motley Fool | TLX | 2 years ago |
ASX Close: 2022 highs in sight as mining rally rolls on
The share market ended within 80 points of this year’s highest close as a mining rally rolled on amid speculation about a commodities “supercycle”. The S&P/ASX 200 rallied 20 points or 0.27 per cent to 7513.7. The index hit its 2022... |
themarketherald.com.au | TLX | 2 years ago |
ASX Update: Lithium miners shine as rally resumes
A lithium-led mining rally kept the ASX on track for this year’s highs. The S&P/ASX 200 climbed 22 points or 0.3 per cent by mid-session. The advance lifted the index briefly to within 100 points of this year’s peak. Lithium min... |
themarketherald.com.au | TLX | 2 years ago |
Stocks of the Hour: Pepper Money, Telix Pharmaceuticals & Iluka Resources
04 Apr 2022 - A snapshot of the stocks on the move featuring Pepper Money (ASX:PPM), Telix Pharmaceuticals (ASX:TLX) & Iluka Resources (ASX:ILU). |
FNN | TLX | 2 years ago |
Telix, GMS and Monash Awarded $23M Federal Government Funding as part of $71M Australian Precision Medicine Enterprise (APME) Project
MELBOURNE, Australia, April 4, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it is part of a $71.2 million Australian Precision Medicine Enterprise (APME) Project, which has been aw... |
FNArena | TLX | 2 years ago |
ScoPo’s Powerplays: Which ASX health stocks are winners from the Federal Budget?
Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in ASX health stocks. Good news for coffee lovers, particularly those w... |
Stockhead | TLX | 2 years ago |
Change of Composition of the Telix Board of Directors
Non-Executive Director Oliver Buck to retire at the Annual General Meeting Tiffany Olson, experienced U.S.-based pharma executive appointed as independent Non-Executive Director MELBOURNE, Australia and INDIANAPOLIS, March 31, 2022 /... |
FNArena | TLX | 2 years ago |
New Video Series “PSMA PET/CT TODAY” Discusses the Future of Prostate Cancer Care with Leading Experts
MELBOURNE, Australia and INDIANAPOLIS, March 29, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the launch of PSMA PET/CT[1] Today, a five-part video series, featuring leading theranostic... |
FNArena | TLX | 2 years ago |
ASX 200 closes 0.7% higher as tech stocks rally
Highlights The ASX 200 closed higher today, gaining 51.90 points or 0.70% to 7,464.30. Wall Street's gains overnight and revived hopes for fresh cease-fire talks between Russia and Ukraine seem to be lifting investor sentiment. In Aus... |
Kalkine Media | TLX | 2 years ago |
Closing Bell: Tech stocks, consumer names lead as small caps close higher
The S&P/ASX Emerging Companies (XEC) Index is racking about 0.3% higher on Tuesday, while the benchmark ASX 200 (XJO) rose 0.7%, buoyed by a resurgent tech sector and a strong performance from consumer discretionary companies ahead of t... |
Stockhead | TLX | 2 years ago |
Telix Granted FDA Orphan Drug Designation for Bone Marrow Conditioning Treatment
MELBOURNE, Australia and INDIANAPOLIS, March 29, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designati... |
FNArena | TLX | 2 years ago |
ASX Large Caps: Bull run continues as ASX 200 notches six gains in a row
ASX 200 notched up sixth day of gains Retailers, tech were best performing sectors Fed Budget to be delivered at 7.30pm AEDT tonight Retailers, Tech lead the way Local shares head into tonight’s Federal Budget in flying colours after clo... |
Stockhead | TLX | 2 years ago |
ASX Close: Blue-chips seal sixth straight advance
The share market closed at a ten-week high as blue-chip healthcare, banking and consumer stocks took the lead during a pause in a two-week commodities rally. The S&P/ASX 200 climbed 52 points or 0.7 per cent to its strongest close... |
themarketherald.com.au | TLX | 2 years ago |
Why Block, Lake Resources, Nearmap, and Telix shares are racing higher
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the time of writing, the benchmark index is up 0.7% to 7,467.2 points. Four ASX shares that are climbing more than most today are listed below... |
Motley Fool | TLX | 2 years ago |
ASX Update: Tech stocks lead rebound as market chases sixth gain
Tech stocks took up the running as the Australian share market rose for a sixth session ahead of tonight’s Federal Budget. The S&P/ASX 200 climbed 59 points or 0.8 per cent to its highest since mid-January. The I.T. sector jumped... |
themarketherald.com.au | TLX | 2 years ago |
Here’s why the Telix (ASX:TLX) share price is leaping higher today
The Telix Pharmaceuticals Ltd (ASX: TLX) share price is heading north during late morning trade following a company announcement. At the time of writing, the biotechnology company’s shares are selling for $4.56 apiece, up 9.88%. What did... |
Motley Fool | TLX | 2 years ago |
Telix and Xiel Sign U.K. and Ireland Distribution Agreement for Illuccix®
MELBOURNE, Australia and LIÈGE, Belgium, March 29, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed an exclusive agreement with Xiel Limited (Xiel) for the distribution of Telix’... |
FNArena | TLX | 2 years ago |
ASX 200 hits 2-month high, Premier Investments disappoints
The Australian market remains resilient to the threat of higher energy prices with the S&P/ASX 200 (ASX: XJO) gaining another 0.3% to finish the week. The result was driven by a rally in the energy, materials and utilities sectors, whic... |
Rask Media | TLX | 2 years ago |
ASX Close: Nine-week high as market bets on commodities
The share market sealed back-to-back weekly gains with a fourth straight advance after strong economic data and a pause in energy prices lifted Wall Street. The S&P/ASX 200 climbed 19 points or 0.26 per cent. The rally lifted the ben... |
themarketherald.com.au | TLX | 2 years ago |
Why Atlas Arteria, Core Lithium, Premier, and Telix shares are dropping
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to finish the week on a high. At the time of writing, the benchmark index is currently up 0.4% to 7,414.6 points. Four ASX shares that have failed to follow the market h... |
Motley Fool | TLX | 2 years ago |
ASX Update: 7400 falls as lithium miners advance
A rebound on Wall Street helped propel the ASX towards a fourth straight gain as a two-week mining rally rolled on. The S&P/ASX 200 climbed 38 points or 0.52 per cent by mid-session. The rally lifted the benchmark above 7400 for the... |
themarketherald.com.au | TLX | 2 years ago |
5 profitable small-cap ASX shares to buy right now: Wilsons
With interest rates almost guaranteed to head upwards this year, multiple experts are emphasising profitability, or at least positive cash flow, as essential for investment. “As interest rates rise, if you don’t have any profit or cash fl... |
Motley Fool | TLX | 2 years ago |
ASX Close: Miners keep market on the up and up
Australian shares inched to a fresh nine-week high as strengthening commodity prices helped the market weather overseas weakness ahead of tonight’s meeting of US and European leaders. Miners and oil producers advanced as the S&P/ASX... |
themarketherald.com.au | TLX | 2 years ago |
Telix Advances Development of Glioblastoma Therapy Program
MELBOURNE, Australia, March 23, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces it has made significant progress in advancing the Company’s glioblastoma multiforme (GBM) therapy candidate TLX101 in... |
FNArena | TLX | 2 years ago |
ASX Close: Miners rally as traders hedge against inflation
The share market rallied to a two-month closing high, bolstered by rising commodity prices and the prospect of record-low rates for some time to come. Strong gains in BHP, Rio Tinto and Newcrest helped lift the S&P/ASX 200 63 points... |
themarketherald.com.au | TLX | 2 years ago |
Telix Pharmaceuticals (ASX:TLX) begins construction of Belgian manufacturing facility
Telix Pharmaceuticals (TLX) provides an update regarding the development of its radiopharmaceutical production facility in Belgium The facility will serve as the primary European manufacturing site for Telix’s products and will play an imp... |
themarketherald.com.au | TLX | 2 years ago |
ASX Update: Shares ride commodity surge to two-month high
Australia’s strength in natural resources fired the share market to a two-month high despite declines on Wall Street as investors fretted about soaring inflation. The S&P/ASX 200 surged 89 points or 1.22 per cent to 7367 by mid-sessi... |
themarketherald.com.au | TLX | 2 years ago |
ASX 200 opens in green; Paladin Energy, BHP Group lead gains
Highlights The benchmark ASX 200 was up 0.76% to 7,347.7 in the first 15 minutes of trading. US stocks took a U-turn on Monday, after rallying for four straight sessions. The energy and materials sectors were roaring today with gains... |
Kalkine Media | TLX | 2 years ago |
Stocks of the Hour: New Hope, Telix Pharmaceuticals & Bubs Australia
22 Mar 2022 - A snapshot of the stocks on the move featuring New Hope (ASX:NHC), Telix Pharmaceuticals (ASX:TLX) & Bubs Australia (ASX:BUB). |
FNN | TLX | 2 years ago |
ASX Close: Oilers steer market to third day of gains
A third day of gains lifted the share market to its highest close in a month as a rebound in commodity prices boosted mining and energy companies. The S&P/ASX 200 rallied 44 points or 0.6 per cent to 7294. The index closed less than... |
themarketherald.com.au | TLX | 2 years ago |
Telix's ZIRCON late-stage kidney cancer imaging study completes enrolment
Telix (ASX:TLX) has announced that its ZIRCON Phase 3 study of investigational kidney cancer imaging agent, TLX250-CDx, has dosed the target enrolment of 252 patients. |
BiotechDispatch | TLX | 2 years ago |